VIGL insider transaction filings
Vigil Neuroscience, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-08-07. Screen VIGL transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for VIGL between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Vigil Neuroscience, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-08-07 | 4 | Atlas Venture Fund XII, L.P. — 10% owner Atlas Venture Associates XII, L.P. — 10% owner Atlas Venture Associates XII, LLC — 10% owner Atlas Venture Opportunity Fund I, L.P. — 10% owner Atlas Venture Associates Opportunity I, L.P. — 10% owner Atlas Venture Associates Opportunity I, LLC — 10% owner | Disposition to issuer (D): 4,808,896 · Disposition to issuer (D): 1,027,978 | EDGAR |
| 2025-08-05 | 4 | Kaufmann Petra — Chief Medical Officer | Disposition to issuer (D): 144,000 (derivative) · Disposition to issuer (D): 330,000 (derivative) | EDGAR |
| 2025-08-05 | 4 | Budd Haeberlein Samantha L. — Director | Disposition to issuer (D): 5,000 · Disposition to issuer (D): 12,000 · Disposition to issuer (D): 18,068 (derivative) · Disposition to issuer (D): 13,928 (derivative) · Disposition to issuer (D): 30,694 (derivative) | EDGAR |
| 2025-08-05 | 4 | Gray David L. F. — Chief Science Officer | Disposition to issuer (D): 125,000 (derivative) · Disposition to issuer (D): 125,000 (derivative) · Disposition to issuer (D): 267,000 (derivative) | EDGAR |
| 2025-08-05 | 4 | Koenig Gerhard — Director | Disposition to issuer (D): 5,000 · Disposition to issuer (D): 18,029 (derivative) · Disposition to issuer (D): 6,954 (derivative) · Disposition to issuer (D): 36,690 (derivative) · Disposition to issuer (D): 18,068 (derivative) · Disposition to issuer (D): 13,928 (derivative) · +2 more | EDGAR |
| 2025-08-05 | 4 | Vitorovic Stefan — Director | Disposition to issuer (D): 5,000 · Disposition to issuer (D): 18,068 (derivative) · Disposition to issuer (D): 13,928 (derivative) · Disposition to issuer (D): 12,155 (derivative) | EDGAR |
| 2025-08-05 | 4 | Ziolkowski Jennifer Lynn — Chief Financial Officer, Director | Disposition to issuer (D): 4,000 · Disposition to issuer (D): 49,968 (derivative) · Disposition to issuer (D): 119,923 (derivative) · Disposition to issuer (D): 96,051 (derivative) · Disposition to issuer (D): 21,635 (derivative) · Disposition to issuer (D): 156,000 (derivative) · +3 more | EDGAR |
| 2025-08-05 | 4 | Bruhn Suzanne Louise — Director | Disposition to issuer (D): 5,000 · Disposition to issuer (D): 24,073 (derivative) · Disposition to issuer (D): 18,068 (derivative) · Disposition to issuer (D): 33,875 (derivative) · Disposition to issuer (D): 13,928 (derivative) · Disposition to issuer (D): 24,310 (derivative) · +1 more | EDGAR |
| 2025-08-05 | 4 | Booth Bruce — Director | Disposition to issuer (D): 5,000 · Disposition to issuer (D): 4,808,896 · Disposition to issuer (D): 1,027,978 · Disposition to issuer (D): 7,577 (derivative) · Disposition to issuer (D): 12,155 (derivative) · Disposition to issuer (D): 9,713 (derivative) · +4 more | EDGAR |
| 2025-08-05 | 4 | Blanchard Cheryl R — Director | Disposition to issuer (D): 5,000 · Disposition to issuer (D): 24,761 (derivative) · Disposition to issuer (D): 24,984 (derivative) · Disposition to issuer (D): 36,690 (derivative) · Disposition to issuer (D): 18,068 (derivative) · Disposition to issuer (D): 13,928 (derivative) · +3 more | EDGAR |
| 2025-08-05 | 4 | Thistle Mary — Director | Disposition to issuer (D): 5,000 · Disposition to issuer (D): 18,068 (derivative) · Disposition to issuer (D): 13,928 (derivative) · Disposition to issuer (D): 24,309 (derivative) · Disposition to issuer (D): 12,155 (derivative) | EDGAR |
| 2025-08-05 | 4 | Magovcevic-Liebisch Ivana — President and CEO, Director | Disposition to issuer (D): 222,687 · Disposition to issuer (D): 369,351 (derivative) · Disposition to issuer (D): 210,629 (derivative) · Disposition to issuer (D): 405,494 (derivative) · Disposition to issuer (D): 43,271 (derivative) · Disposition to issuer (D): 282,000 (derivative) · +3 more | EDGAR |
| 2025-05-23 | 4 | Koenig Gerhard — Director | Grant/award (A): 5,000 @ $0 | EDGAR |
| 2025-05-23 | 4 | Budd Haeberlein Samantha L. — Director | Grant/award (A): 5,000 @ $0 | EDGAR |
| 2025-05-23 | 4 | Vitorovic Stefan — Director | Grant/award (A): 5,000 @ $0 | EDGAR |
| 2025-05-23 | 4 | Bruhn Suzanne Louise — Director | Grant/award (A): 5,000 @ $0 | EDGAR |
| 2025-05-23 | 4 | Booth Bruce — Director | Grant/award (A): 5,000 @ $0 | EDGAR |
| 2025-05-23 | 4 | Blanchard Cheryl R — Director | Grant/award (A): 5,000 @ $0 | EDGAR |
| 2025-05-23 | 4 | Thistle Mary — Director | Grant/award (A): 5,000 @ $0 | EDGAR |
| 2025-03-04 | 4 | Kaufmann Petra — Chief Medical Officer | Grant/award (A): 144,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Gray David L. F. — Chief Science Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Ziolkowski Jennifer Lynn — Chief Financial Officer | Grant/award (A): 156,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Bruhn Suzanne Louise — Director | Grant/award (A): 33,875 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Booth Bruce — Director | Grant/award (A): 48,393 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Magovcevic-Liebisch Ivana — President and CEO, Director | Grant/award (A): 485,000 (derivative) @ $0 | EDGAR |
| 2024-12-19 | 4 | Budd Haeberlein Samantha L. — Director | Purchase (P): 12,000 @ $1.71 | EDGAR |
| 2024-12-19 | 4 | Magovcevic-Liebisch Ivana — President and CEO, Director | Purchase (P): 5,000 @ $1.68 | EDGAR |
| 2024-12-18 | 4 | Magovcevic-Liebisch Ivana — President and CEO, Director | Purchase (P): 5,000 @ $1.67 | EDGAR |
| 2024-12-05 | 4 | Magovcevic-Liebisch Ivana — President and CEO, Director | Purchase (P): 5,000 @ $2.34 | EDGAR |
| 2024-06-07 | 4 | Koenig Gerhard — Director | Grant/award (A): 18,068 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Budd Haeberlein Samantha L. — Director | Grant/award (A): 18,068 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Vitorovic Stefan — Director | Grant/award (A): 18,068 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Bruhn Suzanne Louise — Director | Grant/award (A): 18,068 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Booth Bruce — Director | Grant/award (A): 18,068 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Blanchard Cheryl R — Director | Grant/award (A): 18,068 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Thistle Mary — Director | Grant/award (A): 18,068 (derivative) @ $0 | EDGAR |
| 2024-05-07 | 4 | Verni Christopher — General Counsel | Disposition to issuer (D): 150,000 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0 · Disposition to issuer (D): 85,000 (derivative) @ $0 · Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-05-07 | 4 | Gray David L. F. — Chief Science Officer | Disposition to issuer (D): 267,000 (derivative) @ $0 · Grant/award (A): 267,000 (derivative) @ $0 | EDGAR |
| 2024-05-07 | 4 | Budd Haeberlein Samantha L. — Director | Disposition to issuer (D): 30,694 (derivative) @ $0 · Grant/award (A): 30,694 (derivative) @ $0 · Disposition to issuer (D): 13,928 (derivative) @ $0 · Grant/award (A): 13,928 (derivative) @ $0 | EDGAR |
| 2024-05-07 | 4 | Koenig Gerhard — Director | Disposition to issuer (D): 4,351 (derivative) @ $9.63 · Grant/award (A): 4,351 (derivative) @ $0 · Disposition to issuer (D): 12,155 (derivative) @ $0 · Grant/award (A): 12,155 (derivative) @ $0 · Disposition to issuer (D): 13,928 (derivative) @ $0 · Grant/award (A): 13,928 (derivative) @ $0 | EDGAR |
| 2024-05-07 | 4 | Vitorovic Stefan — Director | Disposition to issuer (D): 12,155 (derivative) @ $0 · Grant/award (A): 12,155 (derivative) @ $0 · Disposition to issuer (D): 13,928 (derivative) @ $0 · Grant/award (A): 13,928 (derivative) @ $0 | EDGAR |
| 2024-05-07 | 4 | Ziolkowski Jennifer Lynn — Chief Financial Officer | Disposition to issuer (D): 110,000 (derivative) @ $0 · Grant/award (A): 110,000 (derivative) @ $0 · Disposition to issuer (D): 135,000 (derivative) @ $0 · Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
| 2024-05-07 | 4 | Bruhn Suzanne Louise — Director | Disposition to issuer (D): 24,310 (derivative) @ $0 · Grant/award (A): 24,310 (derivative) @ $0 · Disposition to issuer (D): 6,235 (derivative) @ $7.62 · Grant/award (A): 6,235 (derivative) @ $0 · Disposition to issuer (D): 13,928 (derivative) @ $0 · Grant/award (A): 13,928 (derivative) @ $0 | EDGAR |
| 2024-05-07 | 4 | Booth Bruce — Director | Disposition to issuer (D): 7,577 (derivative) @ $9.63 · Grant/award (A): 7,577 (derivative) @ $0 · Disposition to issuer (D): 12,155 (derivative) @ $0 · Grant/award (A): 12,155 (derivative) @ $0 · Disposition to issuer (D): 9,713 (derivative) @ $7.62 · Grant/award (A): 9,713 (derivative) @ $0 · +2 more | EDGAR |
| 2024-05-07 | 4 | Thistle Mary — Director | Disposition to issuer (D): 24,309 (derivative) @ $0 · Grant/award (A): 24,309 (derivative) @ $0 · Disposition to issuer (D): 12,155 (derivative) @ $0 · Grant/award (A): 12,155 (derivative) @ $0 · Disposition to issuer (D): 13,928 (derivative) @ $0 · Grant/award (A): 13,928 (derivative) @ $0 | EDGAR |
| 2024-05-07 | 4 | Blanchard Cheryl R — Director | Disposition to issuer (D): 5,017 (derivative) @ $9.63 · Grant/award (A): 5,017 (derivative) @ $0 · Disposition to issuer (D): 12,155 (derivative) @ $0 · Grant/award (A): 12,155 (derivative) @ $0 · Disposition to issuer (D): 6,432 (derivative) @ $7.62 · Grant/award (A): 6,432 (derivative) @ $0 · +2 more | EDGAR |
| 2024-05-07 | 4 | Magovcevic-Liebisch Ivana — President and CEO, Director | Disposition to issuer (D): 282,000 (derivative) @ $0 · Grant/award (A): 282,000 (derivative) @ $0 · Disposition to issuer (D): 370,000 (derivative) @ $0 · Grant/award (A): 370,000 (derivative) @ $0 | EDGAR |
| 2024-03-20 | 4 | Kaufmann Petra — Chief Medical Officer | Grant/award (A): 330,000 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Booth Bruce — Director | Grant/award (A): 34,612 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | Blanchard Cheryl R — Director | Grant/award (A): 24,761 (derivative) @ $0 | EDGAR |
Recent 8-K events — Vigil Neuroscience, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-08-05 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-28 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-07-17 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-05-23 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-05-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-01-23 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-09-17 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VIGL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →